News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Moderna, Inc. announced interim data for mRNA-3927 therapy for propionic acidemia published in Nature, showing signs of clinical benefit and safety. Ongoing global trial evaluates safety and efficacy in participants with PA -
-
-
COMMUNIQUÉ DE PRESSE
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Moderna announces successful clinical readouts for fourth respiratory vaccine candidate meeting Phase 3 endpoints and provides updates on vaccine portfolios, clinical trials, and financial agreements at fifth Vaccines Day event -
-
-
COMMUNIQUÉ DE PRESSE
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Moderna's mRNA-1283 shows higher immune response than mRNA-1273.222 in Phase 3 trial. Next-generation vaccine offers longer shelf life and storage benefits, paving way for flu-COVID combo vaccine, mRNA-1083
